奥氮平与氯氮平治疗难治性精神分裂症的对照研究

Olanzapine(note-min) and clozapine in the treatment of refractory schizophrenia:A contrast study

目的探讨奥氮平(悉敏)治疗难治性精神分裂症的疗效与安全性。方法将65例难治性精神分裂症患者随机分为两组(试验组34例,对照组31例),分别予奥氮平(悉敏)和氯氮平治疗,疗程12周,用阳性症状和阴性症状量表(PANSS)评定疗效,用不良反应量表(TESS)评定不良反应。结果奥氮平(悉敏)治疗有效率为47.1%,氯氮平为45.2%,两组总体疗效比较无统计学差异(P>0.05),但奥氮平(悉敏)不良反应较少而轻。结论奥氮平(悉敏)治疗难治性精神分裂症和氯氮平疗效相当,且安全性高。

Objective To investigate the efficacy and safety of olanzapine （note-rain） in the treatment of refractory schizophrenia. Methods The 65 patients with refractory schizophrenia were randomly divided into two groups （study group： 34 patients, the control group： 31 cases）; and respectively subjected to olanzapine （note-min） in study group, and clozapine treatment in coutrol group; treatment for 12 weeks; Positive Symptoms and Negative Symptoms Scale （PANSS） assessment of efficacy, adverse reactions with the scale （TESS） assessment of adverse reactions were made. Results Olanzapine （note-rain） in the treatment response rate was 47.1%, clozapine 45.2%, overall efficacy difference between the two groups was not statistically significant （P〉0.05）; olanzapine （note-rain） in adverse response was low and mild. Conclusion The therapeutic effect of olanzapine（note-min） in the treatment of refractory schizophrenia is considerable as clozapine, and of high security.